中国医学创新2025，Vol.22Issue(11)：6-10,5.DOI:10.3969/j.issn.1674-4985.2025.11.002
保肺益气丸联合布地格福治疗慢阻肺稳定期效果的研究
Research on the Efficacy of Budesonide Glycopyrronium Bromide and Formoterol Fumarate Combined with Baofei Yiqi Pills in the Treatment of Chronic Obstructive Pulmonary Disease in Stability Period
摘要
Abstract
Objective:To observe the clinical effect of Baofei Yiqi Pills combined with Budesonide Glycopyrronium Bromide and Formoterol Fumarate in the treatment of chronic obstructive pulmonary disease(COPD)in stable period.Method:This study was a prospective study.A total of 60 patients with stable COPD admitted to Leping Hospital of Traditional Chinese Medicine from November 2022 to October 2023 were selected.According to the order of treatment,the patients were divided into the control group(30 cases with odd number)and the observation group(30 cases with even number).The control group was treated with Budesonide Formoterol combined with Tiotropium Bromide inhalation,and the observation group was treated with Baofei Yiqi Pills combined with Budesonide Glycopyrronium Bromide and Formoterol Fumarate.The lung function,therapeutic effect,exercise tolerance[6 min walking distance(6MWD)],the interval of the next acute attack,quality of life and drug safety were compared between the two groups.Result:There were no significant differences in forced expiratory volume in one second(FEV1),forced vital capacity(FVC),peak expiratory flow rate(PEF)and FEV1/FVC between the two groups before treatment(P>0.05).After treatment,FEV1 in the observation group was(2.63±0.28)L,FVC was(3.62±0.36)L,PEF was(5.53±0.37)L/s and FEV1/FVC was(72.65±3.71)%,FEV1,FVC,PEF and FEV1/FVC in the control group were(2.10±0.32)L,(3.19±0.45)L,(4.85±0.41)L/s and(65.84±3.65)%,which were higher than those before treatment,and those in the observation group were higher than those in the control group(P<0.05).The total effective rate of the observation group was 96.67%,which was higher than 73.33%of the control group(P<0.05).There were no significant differences in exercise tolerance and quality of life scores between the two groups before treatment(P>0.05).After treatment,the 6MWD in the observation group was(423.59±38.27)m,which was longer than(375.34±37.56)m in the control group(P<0.05),and the quality of life score in the observation group after treatment was(21.38±5.93)scores,which was lower than(30.26±6.25)scores of the control group(P<0.05).The interval time of the next acute attack in the observation group was(139.94±25.76)d,which was longer than(113.68±27.63)d in the control group(P<0.05).The incidence of adverse reactions in the observation group was 3.33%,which was lower than 20.00%in the control group(P<0.05).Conclusion:Baofei Yiqi Pills combined with Budesonide Glycopyrronium Bromide and Formoterol Fumarate can effectively promote the recovery of lung function in patients with COPD stable period,reduce acute attacks,improve the effectiveness of therapeutic and improve the function of exercise and quality of life,and does not have obvious adverse reactions.关键词
布地格福/保肺益气丸/慢性阻塞性肺疾病/稳定期Key words
Budesonide Glycopyrronium Bromide and Formoterol Fumarate/Baofei Yiqi Pills/Chronic obstructive pulmonary disease/Stability period引用本文复制引用
段林建,胡伶清,程彩洪..保肺益气丸联合布地格福治疗慢阻肺稳定期效果的研究[J].中国医学创新,2025,22(11):6-10,5.基金项目
景德镇市科技计划项目基金(20232SFZC061) （20232SFZC061）
